FLGT

SEC source: 0001209191-18-030475 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,031

F1 · kind: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 10, 2016. The sales were effected in multiple transactions, all at a price of $3.72 per share. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares in each such transaction.

SEC source: 0001209191-18-018504 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,401

F1 · kind: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 10, 2016.

F2 · price: The shares were sold in multiple transactions at prices ranging from $3.75 to $3.81, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-063500 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · As UTMA Custodian

Disclosed balance after: 1,000

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.58 to $3.63, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The shares were purchased by Ming Hsieh as the custodian for his minor child under a Uniform Transfers to Minors Act ("UTMA") account. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-17-063500 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · As UTMA Custodian

Disclosed balance after: 1,000

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.58 to $3.63, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The shares were purchased by Ming Hsieh as the custodian for his minor child under a Uniform Transfers to Minors Act ("UTMA") account. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-17-062379 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,549,707

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.01 to $3.22, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-062016 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,548,108

F2 · price: The shares were purchased in multiple transactions at prices ranging from $3.20 to $3.34, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-062016 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,540,849

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.07 to $3.285, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-061433 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,528,558

F2 · price: The shares were purchased in multiple transactions at prices ranging from $3.19 to $3.41, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-061433 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,526,653

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.27 to $3.30, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-060858 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,526,353

F2 · price: The shares were purchased in multiple transactions at prices ranging from $3.31 to $3.41, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-060859 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,029

F1 · kind: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 10, 2016.

F2 · price: The shares were sold in multiple transactions at $3.22. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares at which the transactions were effected.

SEC source: 0001209191-17-060858 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,523,553

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.22 to $3.39, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-060340 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,515,849

F2 · price: The shares were purchased in multiple transactions at prices ranging from $3.22 to $3.43, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-060340 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,506,464

F1 · price: The shares were purchased in multiple transactions at prices ranging from $3.35 to $3.53, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-048761 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,602

F1 · kind: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 10, 2016.

F2 · price: The shares were sold in multiple transactions at prices ranging from $5.51 to $5.99, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-040258 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,494,944

F2 · price: The shares were purchased in multiple transactions at prices ranging from $5.2999 to $5.385, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-040258 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,482,244

F1 · price: The shares were purchased in multiple transactions at prices ranging from $5.01 to $5.185, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-039732 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,474,944

F2 · price: The shares were purchased in multiple transactions at prices ranging from $4.93 to $5.055, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-039732 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459,944

F1 · price: The shares were purchased in multiple transactions at prices ranging from $4.84 to $5.09, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-17-033500 · doc4.xml · nonDerivative · entry 1

Fulgent Genetics, Inc. · CIK 0001674930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: Represents an award of 2,000 restricted stock units ("RSUs") granted to Dr. Mulay in connection with his appointment as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after May 16, 2017, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date.

SEC source: 0001209191-17-033498 · doc4.xml · nonDerivative · entry 1

Fulgent Genetics, Inc. · CIK 0001674930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,842

F1 · shares: Represents an award of 2,000 restricted stock units ("RSUs") granted to Mr. Bolger in connection with his appointment as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after May 16, 2017, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date.

SEC source: 0001209191-17-039312 · doc4a.xml · nonDerivative · entry 1

Mulay James · CIK 0001684531 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: Represents an award of 2,000 restricted stock units ("RSUs") granted to Dr. Mulay in connection with his reelection as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after May 16, 2017, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date.

F2 · shares: This amendment is being filed because the name of the reporting person was incorrect in the Form 4 as originally filed. This line item is being re-reported in this amendment in order to gain access to the filing system for purposes of filing this amendment.

SEC source: 0001209191-17-039311 · doc4a.xml · nonDerivative · entry 1

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,842

F1 · shares: Represents an award of 2,000 restricted stock units ("RSUs") granted to Mr. Bolger in connection with his reelection as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after May 16, 2017, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date.

F2 · shares: This amendment is being filed because the name of the reporting person was incorrect in the Form 4 as originally filed. This line item is being re-reported in this amendment in order to gain access to the filing system for purposes of filing this amendment.

SEC source: 0001209191-16-147291 · doc4.xml · nonDerivative · entry 1

Mulay James · CIK 0001684531 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · shares: Represents an award of 8,000 restricted stock units ("RSUs") granted to Dr. Mulay in connection with his appointment as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after September 28, 2016, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date.

SEC source: 0001209191-16-147290 · doc4.xml · nonDerivative · entry 1

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,842

F1 · shares: Represents an award of 4,842 restricted stock units ("RSUs") granted to Mr. Bolger in connection with his appointment as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after September 28, 2016, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date.

SEC source: 0001209191-16-144613 · doc4.xml · nonDerivative · entry 2

Yen Yun · CIK 0001684584 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 526,315

F3 · price: The securities were received in the Reorganization in exchange for the cancellation of 4,000,000 of the Predecessor's Class D voting common units.

SEC source: 0001209191-16-144613 · doc4.xml · nonDerivative · entry 1

Yen Yun · CIK 0001684584 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F2 · price: The securities were disposed of and cancelled in the Reorganization in exchange for 526,315 shares of the Issuer's common stock.

SEC source: 0001209191-16-144650 · doc4.xml · nonDerivative · entry 3

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767,659

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F3 · price: The securities were received in the Reorganization in exchange for the cancellation of 13,434,211 Class D voting common units of the Predecessor.

SEC source: 0001209191-16-144650 · doc4.xml · nonDerivative · entry 2

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F2 · price: The securities were disposed of and cancelled in the Reorganization in exchange for 1,767,659 shares of the Issuer's common stock.

SEC source: 0001209191-16-144640 · doc4.xml · derivative · entry 2

Xi Long USA, Inc. · CIK 0001684591 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Predecessor Class D Voting Common Units · 15,394,737 shares

Expires not disclosed

F2 · security: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-2 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F3 · derivative.exercise_price: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof.

F4 · kind: The securities were disposed of and cancelled in the Reorganization, a transaction exempt under Rule 16b-7 under the Exchange Act, in exchange for 2,025,623 shares of the Issuer's common stock.

F4 · price: The securities were disposed of and cancelled in the Reorganization, a transaction exempt under Rule 16b-7 under the Exchange Act, in exchange for 2,025,623 shares of the Issuer's common stock.

F3 · derivative.exercise_date: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof.

F3 · derivative.expiration_date: Prior to the Reorganization, the Predecessor's Class D-2 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with a qualified initial public offering of the Predecessor or a successor thereof.

F2 · derivative.underlying: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-2 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144640 · doc4.xml · nonDerivative · entry 1

Xi Long USA, Inc. · CIK 0001684591 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,025,623

F1 · kind: The securities were received in the Reorganization (as defined below), a transaction exempt under Rule 16b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in exchange for the cancellation of 15,394,737 Class D-2 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC").

F1 · price: The securities were received in the Reorganization (as defined below), a transaction exempt under Rule 16b-7 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in exchange for the cancellation of 15,394,737 Class D-2 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC").

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 8

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,631

Underlying: Issuer Common Stock · 2,631 shares

Expires 2026-06-21

F6 · price: The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units.

F3 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 7

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,631

Underlying: Issuer Common Stock · 2,631 shares

Expires 2026-04-12

F6 · price: The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units.

F2 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 6

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,631

Underlying: Issuer Common Stock · 2,631 shares

Expires 2026-02-22

F6 · price: The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units.

F4 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after February 23, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 5

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares

Expires 2026-06-21

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

F5 · price: The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock.

F3 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 4

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares

Expires 2026-04-12

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

F5 · price: The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock.

F2 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 3

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares

Expires 2026-02-22

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

F5 · price: The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock.

F4 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after February 23, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144562 · doc4.xml · nonDerivative · entry 4

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,736

F5 · price: The securities were received in the Reorganization in exchange for the cancellation of (i) restricted share units relating to 500,000 of the Predecessor's Class D non-voting common units and (ii) 2,500,000 of the Predecessor's Class D voting common units.

F6 · balance_after: Includes 328,947 shares of the Issuer's common stock and restricted stock units relating to 65,789 shares of the Issuer's common stock. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 10, 2016, and 1/16th of the remaining shares vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Kim's continued service for the Predecessor or the Issuer on each vesting date.

SEC source: 0001209191-16-144562 · doc4.xml · nonDerivative · entry 3

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · price: The securities were disposed of and cancelled in the Reorganization in exchange for 328,947 shares of the Issuer's common stock.

SEC source: 0001209191-16-144562 · doc4.xml · nonDerivative · entry 2

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the predecessor's Class D voting common units and all restricted share units relating to the Predecessor's Class D non-voting common units were cancelled in exchange for shares of the Issuer's common stock and restricted stock units relating to shares of the Issuer's common stock, respectively, in each case at a ratio of 7.6-for-1.

F3 · price: The securities were disposed of and cancelled in the Reorganization in exchange for restricted stock units relating to 65,789 shares of the Issuer's common stock.

SEC source: 0001209191-16-144551 · doc4.xml · derivative · entry 8

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Annuity Trust

Disclosed balance after: 0

Underlying: Predecessor Class D Voting Common Units · 10,000,000 shares

Expires not disclosed

F5 · security: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-1 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F7 · derivative.exercise_price: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F9 · price: The securities were disposed of and cancelled in the Reorganization in exchange for 1,315,789 shares of the Issuer's common stock.

F7 · derivative.exercise_date: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F7 · derivative.expiration_date: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F5 · derivative.underlying: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-1 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F4 · ownership.nature: The securities are held of record by the Ming Hsieh Annuity Trust established May 4, 2016 (the "Annuity Trust"), over which Mr. Hsieh possesses sole voting and dispositive power as the sole trustee.

SEC source: 0001209191-16-144551 · doc4.xml · derivative · entry 7

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Predecessor Class D Voting Common Units · 41,381,579 shares

Expires not disclosed

F5 · security: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-1 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F7 · derivative.exercise_price: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F8 · price: The securities were disposed of and cancelled in the Reorganization in exchange for 5,444,944 shares of the Issuer's common stock.

F7 · derivative.exercise_date: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F7 · derivative.expiration_date: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F5 · derivative.underlying: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-1 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144551 · doc4.xml · nonDerivative · entry 4

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,444,944

SEC source: 0001209191-16-144551 · doc4.xml · nonDerivative · entry 3

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Annuity Trust

Disclosed balance after: 1,315,789

F3 · price: The securities were received in the Reorganization (as defined below) in exchange for the cancellation of 10,000,000 of the Predecessor's Class D-1 preferred units.

F4 · ownership.nature: The securities are held of record by the Ming Hsieh Annuity Trust established May 4, 2016 (the "Annuity Trust"), over which Mr. Hsieh possesses sole voting and dispositive power as the sole trustee.

SEC source: 0001209191-16-144551 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,444,944

F2 · price: The securities were received in the Reorganization (as defined below) in exchange for the cancellation of 41,381,579 Class D-1 preferred units of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC").

F1 · balance_after: Prior to the Reorganization (as defined below), Mr. Hsieh was issued one share of the common stock of Fulgent Genetics, Inc. (the "Issuer") upon the Issuer's formation. In the Reorganization, such share was cancelled and extinguished without any conversion thereof and no payment was made with respect thereto. As a result, such share is not reflected as held or beneficially owned by Mr. Hsieh following the Reorganization.

SEC source: 0001209191-16-144562 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the predecessor's Class D voting common units and all restricted share units relating to the Predecessor's Class D non-voting common units were cancelled in exchange for shares of the Issuer's common stock and restricted stock units relating to shares of the Issuer's common stock, respectively, in each case at a ratio of 7.6-for-1.

F2 · price: Reflects an award of restricted share units relating to 500,000 of the Predecessor's Class D non-voting common units. Each restricted share unit represents a contingent right to receive one Class D non-voting common unit of the Predecessor. The units subject to the restricted share units vest over a period of four years, with 1/4th of such units vesting 12 months after August 10, 2016, and 1/16th of the remaining units vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Kim's continued service for the Predecessor or the Issuer on each vesting date.

SEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 2

BOLGER JOHN C · CIK 0001183863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares

Expires 2026-06-21

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

F3 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144650 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,434,211

F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D voting common units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144551 · doc4.xml · derivative · entry 5

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,381,579

Underlying: Predecessor Class D Voting Common Units · 4,618,421 shares

Expires not disclosed

F5 · security: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-1 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

F6 · security: Reflects securities of the Predecessor sold or beneficially owned by Mr. Hsieh as of May 13, 2016.

F7 · derivative.exercise_price: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F7 · derivative.exercise_date: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F7 · derivative.expiration_date: Prior to the Reorganization, the Predecessor's Class D-1 preferred units had no expiration date and were convertible into the Predecessor's Class D voting common units, on a one-for-one basis and for no additional consideration, at any time at the option of the holder and in connection with an initial public offering of the Predecessor or a successor thereof.

F5 · derivative.underlying: Reflects securities of the Predecessor. Fulgent LLC is considered the predecessor of the Issuer following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the Issuer's initial public offering and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all of the Predecessor's Class D-1 preferred units were cancelled in exchange for shares of the Issuer's common stock at a ratio of 7.6-for-1.

SEC source: 0001209191-16-144551 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

F1 · balance_after: Prior to the Reorganization (as defined below), Mr. Hsieh was issued one share of the common stock of Fulgent Genetics, Inc. (the "Issuer") upon the Issuer's formation. In the Reorganization, such share was cancelled and extinguished without any conversion thereof and no payment was made with respect thereto. As a result, such share is not reflected as held or beneficially owned by Mr. Hsieh following the Reorganization.